HealthEquity, Inc. $HQY Holdings Reduced by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. reduced its stake in HealthEquity, Inc. (NASDAQ:HQY) by 14.7%, selling 119,314 shares, and now holds approximately 0.80% of the company, valued at about $61.39 million.
• HealthEquity, Inc. reported a strong EPS of $0.97, surpassing estimates, and set FY 2026 guidance at 3.610-3.78 EPS.
• Recent analyst ratings for HealthEquity are positive, with multiple firms upgrading their price targets, reflecting an average target price of $118.55 and a consensus rating of Buy.

T. Rowe Price Investment Management Inc. decreased its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 14.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 694,720 shares of the company's stock after selling 119,314 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 0.80% of HealthEquity worth $61,393,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of HQY. Invesco Ltd. grew its position in HealthEquity by 50.6% in the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock worth $216,171,000 after purchasing an additional 821,425 shares during the last quarter. Nuveen LLC bought a new stake in shares of HealthEquity during the first quarter valued at about $53,076,000. Westfield Capital Management Co. LP bought a new stake in shares of HealthEquity during the first quarter valued at about $49,787,000. Premier Fund Managers Ltd raised its stake in shares of HealthEquity by 3,601.6% during the first quarter. Premier Fund Managers Ltd now owns 409,992 shares of the company's stock valued at $35,610,000 after purchasing an additional 398,916 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new stake in shares of HealthEquity during the fourth quarter valued at about $32,202,000. Institutional investors own 99.55% of the company's stock.

HealthEquity Stock Down 1.4%

HQY stock opened at $89.82 on Friday. HealthEquity, Inc. has a 12 month low of $73.84 and a 12 month high of $116.65. The firm has a market cap of $7.77 billion, a PE ratio of 65.56, a P/E/G ratio of 1.41 and a beta of 0.54. The firm has a 50 day simple moving average of $96.78 and a 200 day simple moving average of $96.64. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.06 and a quick ratio of 4.06.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its earnings results on Tuesday, June 3rd. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.81 by $0.16. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. The business had revenue of $330.80 million during the quarter, compared to analyst estimates of $322.25 million. During the same period in the prior year, the business earned $0.80 earnings per share. HealthEquity has set its FY 2026 guidance at 3.610-3.78 EPS. Equities research analysts forecast that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In related news, EVP Michael Henry Fiore sold 1,794 shares of the stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $101.73, for a total transaction of $182,503.62. Following the completion of the sale, the executive vice president directly owned 53,225 shares of the company's stock, valued at $5,414,579.25. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jon Kessler sold 97,767 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $112.05, for a total transaction of $10,954,792.35. Following the sale, the director directly owned 75,000 shares of the company's stock, valued at approximately $8,403,750. This represents a 56.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 291,744 shares of company stock valued at $32,705,007 over the last ninety days. Insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HQY shares. JMP Securities increased their price objective on shares of HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a report on Wednesday, June 4th. Raymond James Financial reiterated a "strong-buy" rating and issued a $120.00 price objective (up from $115.00) on shares of HealthEquity in a report on Tuesday, July 8th. Barrington Research increased their price objective on shares of HealthEquity from $112.00 to $125.00 and gave the company an "outperform" rating in a report on Thursday, June 5th. Wall Street Zen upgraded shares of HealthEquity from a "hold" rating to a "buy" rating in a report on Friday, June 6th. Finally, Bank of America increased their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $118.55.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.